浏览全部资源
扫码关注微信
南方医科大学南方医院药学部,广州 510080
硕士。研究方向:药动学。E-mail:work_Zhh@163.com
主任药师,硕士生导师,博士。研究方向:药动学、中药药理。E-mail:wangcx@smu.edu.cn
纸质出版日期:2023-09-30,
收稿日期:2023-06-07,
修回日期:2023-08-28,
扫 描 看 全 文
郑晖晖,周龙玥,赵博欣等.抑乳调经颗粒对奥氮平在大鼠体内药动学的影响 Δ[J].中国药房,2023,34(18):2182-2186.
ZHENG Huihui,ZHOU Longyue,ZHAO Boxin,et al.Effects of Yiru tiaojing granules on the pharmacokinetics of olanzapine in rats[J].ZHONGGUO YAOFANG,2023,34(18):2182-2186.
郑晖晖,周龙玥,赵博欣等.抑乳调经颗粒对奥氮平在大鼠体内药动学的影响 Δ[J].中国药房,2023,34(18):2182-2186. DOI: 10.6039/j.issn.1001-0408.2023.18.02.
ZHENG Huihui,ZHOU Longyue,ZHAO Boxin,et al.Effects of Yiru tiaojing granules on the pharmacokinetics of olanzapine in rats[J].ZHONGGUO YAOFANG,2023,34(18):2182-2186. DOI: 10.6039/j.issn.1001-0408.2023.18.02.
目的
2
探讨抑乳调经颗粒对奥氮平在大鼠体内药动学的影响。
方法
2
分别按单剂量给药和多剂量给药,将SD大鼠随机分4组,每组6只。A、B组大鼠分别单次灌胃奥氮平(5 mg/kg)、奥氮平(5 mg/kg)+抑乳调经颗粒(0.972 g/kg);C、D组大鼠同法给药,每天1次,连续给药14 d。分别在给药前及末次给药后5、15、30 min和1、2、3、6、8、12、24 h于大鼠眼眶静脉丛采血,采用液相色谱-质谱技术测定大鼠的血药浓度,采用DAS 2.0软件计算药动学参数。
结果
2
与A组比较,B组大鼠24 h内的药-时曲线下面积(AUC
0-24 h
)、AUC
0-∞
、峰浓度(
c
max
)均显著降低(
P
<0.05),24 h内的平均滞留时间(MRT
0-24 h
)、MRT
0-∞
、表观清除率(CLz/F)均显著延长(
P
<0.05);C组与D组大鼠的药动学参数比较,差异均无统计学意义(
P
>0.05)。
结论
2
单次联用抑乳调经颗粒会抑制奥氮平在大鼠体内的吸收,长期联用抑乳调经颗粒对奥氮平的药动学过程无明显影响。
OBJECTIVE
2
To investigate the effects of Yiru tiaojing granules on the pharmacokinetics of olanzapine in rats.
METHODS
2
SD rats were randomly divided into 4 groups according to single-dose administration and multiple-dose administration, with 6 rats in each group. Groups A and B were given olanzapine (5 mg/kg) or olanzapine (5 mg/kg)+Yiru tiaojing granules (0.972 g/kg) in a single gavage, and groups C and D were administered with the same method once a day for 14 d. Blood was collected from the orbital venous plexus before administration and 5, 15, 30 min and 1, 2, 3, 6, 8, 12, 24 h after the last administration, respectively. The blood concentration was determined by LC-MS, and the pharmacokinetic parameters were calculated by using DAS 2.0 software.
RESULTS
2
Compared with group A, group B showed a significant decrease in AUC
0-24 h
, AUC
0-∞
and
c
max
(
P
<0.05), and a significant prolongation of MRT
0-24 h
, MRT
0-∞
and CLz/F (
P
<0.05); there was no statistically significant difference in the pharmacokinetic parameters between group C and group D (
P
>0.05).
CONCLUSIONS
2
A single administration of Yiru tiaojing granules can inhibit the absorption of olanzapine in rats, and long-term administration of Yiru tiaojing granules does not have a significant effect on the pharmacokinetic process of olanzapine.
抑乳调经颗粒奥氮平药动学大鼠
olanzapinepharmacokineticsrats
LÄHTEENVUO M,TIIHONEN J. Antipsychotic polypharmacy for the management of schizophrenia:evidence and recommendations[J]. Drugs,2021,81(11):1273-1284.
SIAFIS S,TZACHANIS D,SAMARA M,et al. Antipsychotic drugs:from receptor-binding profiles to metabolic side effects[J]. Curr Neuropharmacol,2018,16(8):1210-1223.
FULTON B,GOA K L. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses[J]. Drugs,1997,53(2):281-298.
PEUSKENS J,PANI L,DETRAUX J,et al. The effects of novel and newly approved antipsychotics on serum prolactin levels:a comprehensive review[J]. CNS Drugs,2014,28(5):421-453.
BAPTISTA T,KIN N M,BEAULIEU S,et al. Obesity and related metabolic abnormalities during antipsychotic drug administration:mechanisms,management and research perspectives[J]. Pharmacopsychiatry,2002,35(6):205-219.
王春霞,潘斌,刘静,等. 抑乳调经颗粒治疗肾虚肝郁型高泌乳素血症的临床疗效观察[J]. 中国药房,2009,20(18):1421-1423.
HUANG X,REN L,HOU L,et al.Paeoniflorin ameliorates antipsychotic-induced hyperprolactinemia in rats by attenuating impairment of the dopamine D2 receptor and TGF-β1 signaling pathways in the hypothalamus and pituitary[J] J Ethnopharmacol,2020,257:112862.
MAEDA K,HISAKA A,ITO K,et al. Classification of drugs for evaluating drug interaction in drug development and clinical management[J]. Drug Metab Pharmacokinet,2021,41:100414.
PERITI P,MAZZEI T,MINI E,et al. Pharmacokinetic drug interactions of macrolides[J]. Clin Pharmacokinet,1992,23(2):106-131.
LOADMAN P M,BIBBY M C. Pharmacokinetic drug interactions with anticancer drugs[J]. Clin Pharmacokinet,1994,26(6):486-500.
ARAVAGIRI M,TEPER Y,MARDER S R. Pharmacokinetics and tissue distribution of olanzapine in rats[J]. Biopharm Drug Dispos,1999,20(8):369-377.
KAPUR S,VANDERSPEK S C,BROWNLEE B A,et al. Antipsychotic dosing in preclinical models is often unre-presentative of the clinical condition:a suggested solution based on in vivo occupancy[J]. J Pharmacol Exp Ther,2003,305(2):625-631.
CALLAGHAN J T,BERGSTROM R F,PTAK L R,et al. Olanzapine: pharmacokinetic and pharmacodynamic profile[J]. Clin Pharmacokinet,1999,37(3):177-193.
0
浏览量
7
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构